Children with uncontrolled, moderate to severe asthma used dupilumab or placebo for 52 weeks. The treatment group had significant decreases in annualized exacerbation rates compared with the ...

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy volunteers.

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

The committee concluded that dupilumab does not represent a cost-effective use of resources, so could not be recommended for treating severe asthma with type 2 inflammation.

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Patients with moderate to severe asthma saw increases in FEV1 within 24 hours after taking a loading dose of rademikibart, ...

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT ...

KT-621 robustly inhibited all the tested cytokines, chemokines, cell infiltrates, and lung remodeling involved in Th2 inflammation in asthma to an extent comparable or superior to an IL-4Rα saturating ...